4559 — Zeria Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapSuper Stock

Annual income statement for Zeria Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	60,427	52,757	59,533	68,383	75,725
Cost of Revenue
Gross Profit	43,783	36,961	42,148	49,489	55,501
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	56,335	48,910	53,399	59,697	65,610
Operating Profit	4,092	3,848	6,134	8,686	10,115
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,920	3,957	5,722	7,273	9,508
Provision for Income Taxes
Net Income After Taxes	2,939	3,155	3,975	6,207	7,695
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,925	3,143	3,961	6,196	7,731
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,925	3,143	3,961	6,196	7,731
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	77.4	76.7	107	163	185
Dividends per Share